IDO and tolerance to tumors

David H. Munn, Andrew L. Mellor

Research output: Contribution to journalArticle

201 Citations (Scopus)

Abstract

Tumors create a pathological state of tolerance towards tumor-associated antigens. The mechanisms by which this occurs are still largely unknown. Recent studies suggest that one mechanism contributing to this phenomenon could be tryptophan catabolism carried out by the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO). IDO can be expressed by tumor cells themselves, and we propose that the recruitment of antigen-presenting cells expressing IDO to tumor-draining lymph nodes might constitute another potent mechanism for inducing tolerance to tumor-derived antigens. Therapeutic strategies based on blocking this pathway might represent a novel class of adjuvants for tumor immunotherapy.

Original languageEnglish (US)
Pages (from-to)15-18
Number of pages4
JournalTrends in Molecular Medicine
Volume10
Issue number1
DOIs
StatePublished - Jan 2004

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Neoplasm Antigens
Neoplasms
Antigen-Presenting Cells
Tryptophan
Immunotherapy
Lymph Nodes
Enzymes

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology

Cite this

IDO and tolerance to tumors. / Munn, David H.; Mellor, Andrew L.

In: Trends in Molecular Medicine, Vol. 10, No. 1, 01.2004, p. 15-18.

Research output: Contribution to journalArticle

Munn, David H. ; Mellor, Andrew L. / IDO and tolerance to tumors. In: Trends in Molecular Medicine. 2004 ; Vol. 10, No. 1. pp. 15-18.
@article{1239df29996d43528f61f6e95e3be4bc,
title = "IDO and tolerance to tumors",
abstract = "Tumors create a pathological state of tolerance towards tumor-associated antigens. The mechanisms by which this occurs are still largely unknown. Recent studies suggest that one mechanism contributing to this phenomenon could be tryptophan catabolism carried out by the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO). IDO can be expressed by tumor cells themselves, and we propose that the recruitment of antigen-presenting cells expressing IDO to tumor-draining lymph nodes might constitute another potent mechanism for inducing tolerance to tumor-derived antigens. Therapeutic strategies based on blocking this pathway might represent a novel class of adjuvants for tumor immunotherapy.",
author = "Munn, {David H.} and Mellor, {Andrew L.}",
year = "2004",
month = "1",
doi = "10.1016/j.molmed.2003.11.003",
language = "English (US)",
volume = "10",
pages = "15--18",
journal = "Trends in Molecular Medicine",
issn = "1471-4914",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - IDO and tolerance to tumors

AU - Munn, David H.

AU - Mellor, Andrew L.

PY - 2004/1

Y1 - 2004/1

N2 - Tumors create a pathological state of tolerance towards tumor-associated antigens. The mechanisms by which this occurs are still largely unknown. Recent studies suggest that one mechanism contributing to this phenomenon could be tryptophan catabolism carried out by the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO). IDO can be expressed by tumor cells themselves, and we propose that the recruitment of antigen-presenting cells expressing IDO to tumor-draining lymph nodes might constitute another potent mechanism for inducing tolerance to tumor-derived antigens. Therapeutic strategies based on blocking this pathway might represent a novel class of adjuvants for tumor immunotherapy.

AB - Tumors create a pathological state of tolerance towards tumor-associated antigens. The mechanisms by which this occurs are still largely unknown. Recent studies suggest that one mechanism contributing to this phenomenon could be tryptophan catabolism carried out by the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO). IDO can be expressed by tumor cells themselves, and we propose that the recruitment of antigen-presenting cells expressing IDO to tumor-draining lymph nodes might constitute another potent mechanism for inducing tolerance to tumor-derived antigens. Therapeutic strategies based on blocking this pathway might represent a novel class of adjuvants for tumor immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0842286646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0842286646&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2003.11.003

DO - 10.1016/j.molmed.2003.11.003

M3 - Article

C2 - 14720581

AN - SCOPUS:0842286646

VL - 10

SP - 15

EP - 18

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

IS - 1

ER -